Illumina, Inc. ILMN announced Monday a deal to buy privately held Grail, which focuses on early detection of multiple cancers, for $8 billion in cash and stock. The Illumina Analysts: Baird analyst Catherine Ramsey Schulte maintained a Neutral rating on Illumina shares and lowered the price target from $335 to $281. JPMorgan analyst Tycho Peterson downgraded Illumina shares from Overweight to Neutral and reduced the price target from $390 to $280. Wells Fargo Securities analyst Dan Leonard maintained an Underweight rating and took the price target from $290 down to $250.